Last reviewed · How we verify
BDP
BDP is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
BDP is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | BDP |
|---|---|
| Also known as | QNASL®, Beclomethasone dipropionate |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate (BDP) is a topical corticosteroid delivered via inhalation that suppresses local inflammatory responses in the respiratory tract. It binds to glucocorticoid receptors on immune cells and epithelial cells, reducing the production of inflammatory mediators and decreasing airway hyperresponsiveness. The drug acts locally in the lungs with minimal systemic absorption when used at therapeutic doses.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia
- Tremor
- Headache
- Throat irritation
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP CI brief — competitive landscape report
- BDP updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI